Literatur
- 1
Bernard J, Weil M, Boiron M, Jacquillat C, Flandrin G, Gemon M F.
Acute
promyelocytic leukemia. Results of treatment by Daunorubicin.
Blood.
1973;
41
489-496
- 2
Büchner T, Hiddemann W, Wörmann B. et al .
Double induction strategy for acute myeloid
leukemia. The effect of high-dose cytarabine with mitoxantrone instead
of standard-dose cytarabine with daunorubicin and 6-thioguanine.
A randomized trial by the German AML Cooperative Group.
Blood.
1999;
93
6116-4124
- 3
Burnett A K, Grimwade D, Solomon E, Wheatley K, Goldstone A H.
Presenting
white blood cell counts and kinetics of molecular remission predict
prognosis in acute promyelocytic leukemia treated with all-trans
retinoic acid. Results of the randomized MRC trial.
Blood.
1999;
93
4131-4143
- 4
Chen Z Y, Xue Y Q, Zhang R. et al .
A clinical and experimental study on all-trans
retinoic acid-treated acute promyelocytic leukemia patients.
Blood.
1991;
78
1413-1419
- 5
Chen G Q, Shi X G, Tang W. et al .
Use of Trioxide (As203)in the treatment
of acute promyelocytic leukemia. (APL). I. As2O3 exerts dose-dependent
dual effects on APL cells.
Blood.
1997;
89
3345-3353
- 6
Chen Z.
Treatment
of acute promyelocytic leukemia with arsenic compounds. In vitro
and in vivo studies.
Semin Hematol.
2001;
38
26-36
- 7
De Botton S, Dombret H, Sanz M. et al .
Incidence, clinical features and outcome
of all trans-retinoid syndrome in 413 cases of newly diagnosed acute
promyelocytic leukemia.
Blood.
1998;
92
2712-2718
- 8
Degos L, Dombret H, Chomienne C. et al .
All-trans
retinoic acid as a differentiating agent in the treatment of acute
promyelocytic leukemia.
Blood.
1995;
85
2643-2653
- 9
De Witte T, Suciu S, Zittoun R. et al .
The type of anthrazykline administered
during remission induction and consolidation therapy of AML has
an impact on feasibility of subsequent autologous or allogeneic
transplantation and induced marrow toxicity: preliminary results
of the EORTC-GIMEMA AML-10 randomized trial.
Blood.
2000;
96
503a
(suppl 1))
- 10
Diviero D, Rossi V, Avvisati G. et al .
Early detection of relapse by prospective
reverse transcriptase-polymerase chain reaction analysis of the
PML/RARα fusion gene in patients with acute promyelocytic
leukemia enrolled in the GIMEMA-AIEOP multicenter »AIDA« trial.
Blood.
1998;
92
784-789
- 11
Estey E H, Giles F, Kantarjian H. et al .
Molecular remissions induced by liposomal-encapsulated
all-trans retinoic acid in newly diagnosed acute promyelocytic leukemia.
Blood.
1999;
94
2230-2235
- 12
Fenaux P, Castaigne S, Dombret H. et al .
All-trans retinoic acid followed by intensive
chemotherapy gives a high complete remission rate and may prolong
remissions in newly diagnosed acute promyelocytic leukemia. A pilot
study on 26 cases.
Blood.
1992;
80
2176-2181
- 13
Fenaux P, Le D eley MC, Castaigne S. et al .
Effect of all-trans retinoic acid in newly
diagnosed acute promyelocytic leukemia. Results of a multicentar
randomized study.
Blood.
1993;
82
3241-3249
- 14
Fenaux P, Chastang C, Chevret S. et al .
A randomized comparison of all transretinoic
acid (ATRA) followed by chemotherapy and ATRA plus chemotherapy
and the role of maintenance therapy in newly diagnosed acute promyelocytic
leukemia.
Blood.
1999;
94
1192-1200
- 15
Frankel S R, Eardley A, Heller G. et al .
All-trans retinoic acid for acute promyelocytic
leukemia. Results of the New York Study.
Ann Intern Med.
1994;
120
278-286
- 16
Grimwade D.
The
pathogenesis of acute promyelocytic leukemia: evaluation of the
role of molecular diagnosis and monitoring in the management of
the disease.
Br J Haematol.
1999;
106
591-613
- 17
Guidez F, Ivins S, Zhu J, Söderström M, Waxman S, Zelent A.
Reduced
retinoic acid-sensitivities of nuclear receptor corepressor binding
to PML- and PLZF-RARα underlie molecular pathogenesis and treatment
in acute promyelocytic leukemia.
Blood.
1998;
91
2634-2642
- 18
Head D, Kenneth J K, Weick J. et al .
Effect
of aggressive daunomycin therapy on survival in acute promyelocytic
leukemia.
Blood.
1995;
86
1717-1728
- 19
Hiddemann W.
Cytosine
arabinoside in the treatment of acute myeloid leukemia. The role
and place of high-dose regimens.
Ann Hematol.
1991;
62
119-128
- 20
Huang M, Ye Y, Chen S, Chai S, Lu J X, Lin Z, Gu L, Wang Z.
Use
of all-trans retinoic acid in the treatment of acute promyelocytic
leukemia.
Blood.
1988;
72
567-572
- 21
Kakizuka A, Miller W H, Umesono K. et al .
Chromosomal translocation t(15;17) in human
acute promyelocytic leukemia fuses RARα with a novel putative
transcription factor, PML.
Cell.
1991;
66
663-674
- 22
Kanamaru A, Takemoto Y, Tanimoto M. et al .
All-trans retinoic acid for the treatment
of newly diagnosed acute promyelocytic leukemia.
Blood.
1995;
85
1202-1206
- 23
Kantarjian H M, Keating M J, Walters R S, Smith T L, McCredie K, Freireich E J.
Role of
maintenance chemotherapy in acute promyelocytic leukemia.
Cancer.
1987;
59
1258-1263
- 24
Lengfelder E, Reichert A, Hehlmann R. et al .
Effects of high dose cytarabin as part
of double induction strategy in acute promyelocytic leukemia and
results of combination with all-trans retinoic acid.
Blood.
1997;
90
330a
(suppl 1))
- 25
Lengfelder E, Reichert A, Schoch C. et al .
Double induction strategy including high
dose cytarabine in combination with all-trans retinoic acid. Effects
in patients with newly diagnosed acute promyelocytic leukemia.
Leukemia.
2000;
14
1362-1370
- 26
Lo Coco F, Diverio D, Avvisati G. et al .
Therapy of molecular relapse in acute promyelocytic
leukemia.
Blood.
1999;
94
2225-2229
- 27
Mandelli F, Labopoin M, Granena A. et al .
European survey of bone marrow transplantation
in acute promyelocytic leukemia (M3).
Bone Marrow Transplantation.
1994;
14
293-298
- 28
Mandelli F, Diviero D, Avvisati G. et al .
Molecular remission in PML/RAR(-positive
acute promyelocytic leukemia by combined all-trans retinoic acid
and Idarubicin (AIDA) therapy.
Blood.
1997;
90
1014-1021
- 29
Niu C, Yan H, Yu T, Sun H P. et al .
Studies on treatment of acute promyelocytic
leukemia with arsenic trioxide: remission induction, follow-up,
and molecular monitoring in 11 newly diagnosed and 47 relapsed acute
promyelocytic leukemia patients.
Blood.
1999;
94
3315-3324
- 30
Runde V, Aul C.
Treatment
of acute promyelocytic leukemia.
Onkologie.
1992;
15
356-363
- 31
Sanz M A, Martín G, Rayón C. et al .
A modified AIDA protocol with anthracycline-based
consolidation results in high antileukemic efficacy and reduced
toxicity in newly diagnosed PML/RARa-positve acute promyelocytic
leukemia.
Blood.
1999;
94
3015-3021
- 32
Sanz M A, Lo C oco F, Martín G. et al .
Definition of relapse risk and role of
nonanthracycline drugs for consolidation in patients with acute
promyelocytic leukemia. A joint study of the PETHEMA and GIMEMA
cooperative groups.
Blod.
2000;
96
1247-1253
- 33
Saußele S, Lengfelder E, Weißer A. et al .
Monitoring of minimal residual disease
by RT-PCR of PML/RARα und RARα/PML
fusion transcripts in acute promyelocytic leukemia.
Onkologie.
2000;
23
95
(Suppl 7))
- 34
Shen Z X, Chen G Q, Ni J H. et al .
Use of arsenic trioxide (As2O3) in the treatment
of acute promyelocytic leukemia (APL). II. Clinical efficacy and
pharmacokinetics in relapsed patients.
Blood.
1997;
89
3354-3360
- 35
Tallman M S, Kwaan H C.
Reassessing
the hemostatic disorder associated with acute promyelocytic leukemia.
Blood.
1992;
79
543-553
- 36
Tallman M S, Andersen J W, Schiffer C A. et al .
All-trans retinoic acid in acute promyelocytic
leukemia.
N Engl J Med.
1997;
337
1021-1028
- 37
Tallman M S, Andersen J W, Schiffer C A. et al .
All-trans retinoic acid in acute promyelocytic
leukemia long-term outcome results and prognostic factor analysis
from intergroup protocol 0129.
Blood.
1999;
94
698a
(Suppl 1))
- 38
Tallman M S, Andersen J W, Schiffer C A. et al .
Clinical description of 44 patients with
acute promyelocytic leukemia who developed the retinoic acid syndrome.
Blood.
2000;
95
90-95
- 39
Warrell R P.
Retinoic
resistance in acute promyelocytic leukemia. New mechanisms, strategies,
and implications.
Blood.
1993;
82
1949-1953
- 40
Warrell R P, Maslak P, Eardley A, Heller G, Miller W H, Frankel S R.
Treatment
of acute promyelocytic leukemia with all-trans retinoic acid. An
update of the New York experience.
Leukemia.
1994;
8
929-933
- 41
Wiley J S, Firkin F C.
Reduction of
pulmonary toxicity by predisolone prophylaxis during all-trans retinoic
acid treatment of acute promyelocytic leukemia.
Leukemia.
1995;
9
774-778
Korrespondenz
PD Dr. Eva Lengfelder
III. Med. Klinik Mannheim
Wiesbadenerstraße 7-11
68305 Mannheim
Telefon: 0621/383-4110
Fax: 0621/383-4201
